E Ohmoto
About
In The Last Decade
E Ohmoto
13 papers receiving 235 citations
Peers
Comparison fields: 5 of 47
- Molecular Biology 200
- Hematology 199
- Biochemistry 60
- Public Health, Environmental and Occupational Health 49
- Oncology 29
Countries citing papers authored by E Ohmoto
This map shows the geographic impact of E Ohmoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Ohmoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Ohmoto more than expected).
Fields of papers citing papers by E Ohmoto
This network shows the impact of papers produced by E Ohmoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Ohmoto. The network helps show where E Ohmoto may publish in the future.
Co-authorship network of co-authors of E Ohmoto
This figure shows the co-authorship network connecting the top 25 collaborators of E Ohmoto. A scholar is included among the top collaborators of E Ohmoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Ohmoto. E Ohmoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. | 1 |
| 3 | 182 | |
| 4 | All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. | 22 |
| 5 | Bi-phenotypic t(9;22)-positive leukemia cell lines from a patient with acute leukemia: NALM-20, established at the onset; and NALM-21, NALM-22 and NALM-23, established after relapse. | 15 |
| 6 | 2 | |
| 7 | [Myelodysplasia with hypoplastic marrow]. | 0 |
| 8 | 2 | |
| 9 | 16 | |
| 10 | [Effects of interferon and its inducers on neutrophil chemiluminescence]. | 3 |
| 11 | [Clinical effects of human lymphoblastoid interferon in patients with hematologic neoplasms]. | 1 |
| 12 | Superoxide anion (O2) production by neutrophils in leukemia and related diseases. | 1 |
| 13 | [Clinical studies on superoxide production of neutrophils in patients with acute leukemia]. | 1 |
| 14 | [Clinical effects of ceftizoxime and latamoxef on infections in acute leukemia]. | 1 |
| 15 | 2 | |
| 16 | [Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.